UY33872A - Uso de análogos de glucagón acilados - Google Patents
Uso de análogos de glucagón aciladosInfo
- Publication number
- UY33872A UY33872A UY0001033872A UY33872A UY33872A UY 33872 A UY33872 A UY 33872A UY 0001033872 A UY0001033872 A UY 0001033872A UY 33872 A UY33872 A UY 33872A UY 33872 A UY33872 A UY 33872A
- Authority
- UY
- Uruguay
- Prior art keywords
- acilated
- glucagon analogs
- glucagon
- analogs
- image
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La invención se refiere a procedimientos para tratar trastornos metabólicos, incluyendo diabetes, mediante el uso de una combinación de un análogo de glucagón acilado y un análogo de insulina. La invención también se refiere a un kit que incluye un análogo de glucagón acilado y un análogo de insulina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161434698P | 2011-01-20 | 2011-01-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY33872A true UY33872A (es) | 2012-08-31 |
Family
ID=45607302
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001033872A UY33872A (es) | 2011-01-20 | 2012-01-20 | Uso de análogos de glucagón acilados |
Country Status (20)
Country | Link |
---|---|
US (2) | US20140011733A1 (es) |
EP (1) | EP2665487A1 (es) |
JP (1) | JP2014504597A (es) |
KR (1) | KR20140043709A (es) |
CN (1) | CN103491975B (es) |
AR (1) | AR085086A1 (es) |
AU (1) | AU2012208349A1 (es) |
BR (1) | BR112013018269A2 (es) |
CA (1) | CA2824397A1 (es) |
CL (1) | CL2013002085A1 (es) |
CO (1) | CO6761400A2 (es) |
EA (1) | EA201390796A1 (es) |
MA (1) | MA34913B1 (es) |
MX (1) | MX2013008005A (es) |
PE (1) | PE20140969A1 (es) |
SG (1) | SG192038A1 (es) |
TN (1) | TN2013000251A1 (es) |
TW (1) | TW201247702A (es) |
UY (1) | UY33872A (es) |
WO (1) | WO2012098462A1 (es) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102292347A (zh) | 2008-12-15 | 2011-12-21 | 西兰制药公司 | 胰高血糖素类似物 |
WO2010070253A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
AP2011005774A0 (en) | 2008-12-15 | 2011-06-30 | Zealand Pharma As | Glucagon analogues. |
JP5635532B2 (ja) | 2008-12-15 | 2014-12-03 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
GEP20146056B (en) | 2009-07-13 | 2014-03-10 | Zealand Pharma As | Acylated glucagon analogues |
UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
NZ604208A (en) | 2010-06-24 | 2014-10-31 | Zealand Pharma As | Glucagon analogues |
AR088161A1 (es) | 2011-09-23 | 2014-05-14 | Novo Nordisk As | Analogos de glucagon |
NZ702333A (en) | 2012-05-03 | 2017-06-30 | Zealand Pharma As | Gip-glp-1 dual agonist compounds and methods |
WO2014016300A1 (en) | 2012-07-23 | 2014-01-30 | Zealand Pharma A/S | Glucagon analogues |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
AU2014241743B2 (en) * | 2013-03-14 | 2018-07-05 | Indiana University Research And Technology Corporation | Insulin-incretin conjugates |
JP6594856B2 (ja) | 2013-04-18 | 2019-10-23 | ノヴォ ノルディスク アー/エス | 医療用の安定な遷延性glp−1/グルカゴン受容体コアゴニスト |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
AR098065A1 (es) | 2013-10-17 | 2016-04-27 | Zealand Pharma As | Análogos de glucagón acilados |
WO2015067716A1 (en) | 2013-11-06 | 2015-05-14 | Zealand Pharma A/S | Glucagon-glp-1-gip triple agonist compounds |
MX2016005556A (es) | 2013-11-06 | 2016-07-15 | Zealand Pharma As | Compuestos agonistas duales de gip-glp-1 y procedimientos. |
AR098616A1 (es) | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Péptido para el tratamiento de hipoglicemia severa |
BR112016016578A2 (pt) | 2014-01-20 | 2017-10-03 | Hanmi Pharm Ind Co Ltd | Insulina de ação prolongada e uso daanálogo de insulina, polinucleotídeo, vetor de expressão, transformante, insulina de ação prolongada bem como seu método de preparação e formulação da mesma, conjugado, e uso do mesmo mesma |
AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
TWI684458B (zh) | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及glp-1/昇糖素雙重促效劑之治療糖尿病之組成物 |
EP3151852A1 (en) | 2014-06-04 | 2017-04-12 | Novo Nordisk A/S | Glp-1/glucagon receptor co-agonists for medical use |
EP3206710B1 (en) | 2014-09-24 | 2020-05-06 | Indiana University Research & Technology Corporation | Incretin-insulin conjugates |
US10253078B2 (en) | 2014-10-29 | 2019-04-09 | Zealand Pharma A/S | GIP agonist compounds and methods |
DK3283507T3 (da) * | 2015-04-16 | 2020-01-02 | Zealand Pharma As | Acyleret glucagonanalog |
UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
BR102015031283A2 (pt) * | 2015-12-14 | 2018-09-18 | Univ Rio De Janeiro | Bioconjugado de amilina humana ou de análogos de amilinanão agregantes, composição, métodos para a preparação deuma composição, para o tratamento de uma doença oucondição e para estabilizar um composto amilino-mimético, e,medicamento |
US20190175744A1 (en) * | 2016-03-18 | 2019-06-13 | Merck Sharp & Dohme Corp. | Insulin-incretin conjugates |
US11058775B2 (en) | 2016-04-26 | 2021-07-13 | Merck Sharp & Dohme Corp. | Insulin dimer-incretin conjugates |
CN110546161B (zh) | 2016-09-23 | 2024-01-26 | 韩美药品股份有限公司 | 对胰岛素受体具有降低的结合力的胰岛素类似物及其用途 |
CN110536899B (zh) | 2017-03-23 | 2023-12-12 | 韩美药品株式会社 | 对胰岛素受体具有降低的亲和力的胰岛素类似物复合物及其用途 |
MX2021007124A (es) * | 2018-12-21 | 2021-08-11 | Hanmi Pharm Ind Co Ltd | Composicion farmaceutica que incluye insulina y glucagon. |
US20230293639A1 (en) * | 2020-06-11 | 2023-09-21 | Abvance Therapeutics, Inc. | Systems, devices, compositions, and methods for treating diabetes |
KR20240099485A (ko) * | 2021-11-19 | 2024-06-28 | 메드샤인 디스커버리 아이엔씨. | 스테이플화 펩타이드 및 이의 용도 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3837825A1 (de) | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
US6869930B1 (en) | 1993-09-17 | 2005-03-22 | Novo Nordisk A/S | Acylated insulin |
UA45321C2 (uk) | 1993-09-17 | 2002-04-15 | Ново Нордіск А/С | Похідне інсуліну, фармацевтична композиція для лікування діабету та спосіб лікування діабету |
US6011007A (en) | 1993-09-17 | 2000-01-04 | Novo Nordisk A/S | Acylated insulin |
US5461031A (en) | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
US5866538A (en) | 1996-06-20 | 1999-02-02 | Novo Nordisk A/S | Insulin preparations containing NaCl |
RU2214419C2 (ru) | 1996-08-30 | 2003-10-20 | Ново Нордиск А/С | Glp-1 производные |
ES2239364T3 (es) | 1996-09-09 | 2005-09-16 | Zealand Pharma A/S | Sintesis de peptidos en fase solida. |
DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
RU2001128068A (ru) | 1999-03-17 | 2004-02-20 | Ново Нордиск А/С (DK) | Способ ацилирования пептидов и новые ацилирующие агенты |
AU2002346491A1 (en) | 2001-12-19 | 2003-07-09 | Eli Lilly And Company | Crystalline compositions for controlling blood glucose |
CA2468100A1 (en) | 2001-12-20 | 2003-07-03 | Eli Lilly And Company | Insulin molecule having protracted time action |
DE10227232A1 (de) | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
EP1620465A2 (en) | 2003-04-29 | 2006-02-01 | Eli Lilly And Company | Insulin analogs having protracted time action |
KR101349808B1 (ko) | 2005-06-13 | 2014-02-13 | 임페리얼 이노베이션스 리미티드 | 섭취행동에 관한 신규 화합물들 및 이들의 효능 |
US8343914B2 (en) | 2006-01-06 | 2013-01-01 | Case Western Reserve University | Fibrillation resistant proteins |
CA2638800A1 (en) | 2006-02-22 | 2007-09-07 | Merck & Co., Inc. | Oxyntomodulin derivatives |
ES2554773T3 (es) | 2006-10-04 | 2015-12-23 | Case Western Reserve University | Insulina y análogos de la insulina resistentes a la fibrilación |
TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
WO2008101017A2 (en) | 2007-02-15 | 2008-08-21 | Indiana Unversity Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
EP2158214B1 (en) | 2007-06-15 | 2011-08-17 | Zealand Pharma A/S | Glucagon analogues |
MX2010005317A (es) | 2007-11-20 | 2010-06-02 | Ambrx Inc | Polipeptidos de insulina modificados y sus usos. |
DE102008003568A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
DE102008003566A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
CN101970476B (zh) | 2008-01-09 | 2014-08-27 | 塞诺菲-安万特德国有限公司 | 具有超延迟时效特征的胰岛素衍生物 |
PL2229407T3 (pl) | 2008-01-09 | 2017-06-30 | Sanofi-Aventis Deutschland Gmbh | Nowe pochodne insuliny o ekstremalnie spowolnionym profilu czasu działania |
US8993516B2 (en) | 2008-04-14 | 2015-03-31 | Case Western Reserve University | Meal-time insulin analogues of enhanced stability |
RU2010147076A (ru) | 2008-04-22 | 2012-05-27 | Кейз Вестерн Ризев Юнивесити (Us) | Аналоги инсулина специфичные к изоформам |
TWI451876B (zh) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
WO2009155258A2 (en) | 2008-06-17 | 2009-12-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
CA2727161A1 (en) * | 2008-06-17 | 2009-12-23 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers |
PL219335B1 (pl) | 2008-07-04 | 2015-04-30 | Inst Biotechnologii I Antybiotyków | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna |
BRPI0916560A2 (pt) | 2008-07-31 | 2015-11-10 | Univ Case Western Reserve | análogo de insulina, ácido nucléico, vetor de expressão, célula hospedeira e método de tratamento de um paciente. |
AP2011005774A0 (en) * | 2008-12-15 | 2011-06-30 | Zealand Pharma As | Glucagon analogues. |
JP5635532B2 (ja) * | 2008-12-15 | 2014-12-03 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
WO2010070253A1 (en) * | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
CN102292347A (zh) * | 2008-12-15 | 2011-12-21 | 西兰制药公司 | 胰高血糖素类似物 |
AU2009335715B2 (en) | 2008-12-19 | 2016-09-15 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
CA2747490C (en) | 2008-12-19 | 2017-02-14 | Indiana University Research And Technology Corporation | Insulin analogs |
CN101519446A (zh) | 2009-03-31 | 2009-09-02 | 上海一就生物医药有限公司 | 一种重组人胰岛素及其类似物的制备方法 |
GEP20146056B (en) * | 2009-07-13 | 2014-03-10 | Zealand Pharma As | Acylated glucagon analogues |
EA023925B1 (ru) * | 2010-04-27 | 2016-07-29 | Зилэнд Фарма А/С | Пептидные конъюгаты агонистов рецептора glp-1 и их применение |
UY33462A (es) * | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
-
2012
- 2012-01-20 WO PCT/IB2012/000134 patent/WO2012098462A1/en active Application Filing
- 2012-01-20 EA EA201390796A patent/EA201390796A1/ru unknown
- 2012-01-20 BR BR112013018269A patent/BR112013018269A2/pt not_active IP Right Cessation
- 2012-01-20 PE PE2013001533A patent/PE20140969A1/es not_active Application Discontinuation
- 2012-01-20 SG SG2013055090A patent/SG192038A1/en unknown
- 2012-01-20 CA CA2824397A patent/CA2824397A1/en not_active Abandoned
- 2012-01-20 JP JP2013549906A patent/JP2014504597A/ja active Pending
- 2012-01-20 MA MA36191A patent/MA34913B1/fr unknown
- 2012-01-20 KR KR1020137018388A patent/KR20140043709A/ko not_active Application Discontinuation
- 2012-01-20 UY UY0001033872A patent/UY33872A/es not_active Application Discontinuation
- 2012-01-20 TW TW101102724A patent/TW201247702A/zh unknown
- 2012-01-20 CN CN201280005920.1A patent/CN103491975B/zh not_active Expired - Fee Related
- 2012-01-20 MX MX2013008005A patent/MX2013008005A/es not_active Application Discontinuation
- 2012-01-20 EP EP12704117.6A patent/EP2665487A1/en not_active Withdrawn
- 2012-01-20 AU AU2012208349A patent/AU2012208349A1/en not_active Abandoned
- 2012-01-20 US US13/980,087 patent/US20140011733A1/en not_active Abandoned
- 2012-01-20 AR ARP120100195A patent/AR085086A1/es unknown
-
2013
- 2013-06-11 TN TNP2013000251A patent/TN2013000251A1/fr unknown
- 2013-07-11 CO CO13165262A patent/CO6761400A2/es unknown
- 2013-07-19 CL CL2013002085A patent/CL2013002085A1/es unknown
-
2015
- 2015-09-17 US US14/857,067 patent/US20160000883A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
TW201247702A (en) | 2012-12-01 |
NZ612719A (en) | 2015-05-29 |
TN2013000251A1 (en) | 2014-11-10 |
JP2014504597A (ja) | 2014-02-24 |
MA34913B1 (fr) | 2014-02-01 |
MX2013008005A (es) | 2013-08-21 |
EA201390796A1 (ru) | 2014-07-30 |
AU2012208349A1 (en) | 2013-07-18 |
SG192038A1 (en) | 2013-08-30 |
US20160000883A1 (en) | 2016-01-07 |
EP2665487A1 (en) | 2013-11-27 |
CO6761400A2 (es) | 2013-09-30 |
CL2013002085A1 (es) | 2013-12-06 |
BR112013018269A2 (pt) | 2017-06-06 |
AR085086A1 (es) | 2013-09-11 |
WO2012098462A1 (en) | 2012-07-26 |
CA2824397A1 (en) | 2012-07-26 |
CN103491975B (zh) | 2016-05-11 |
US20140011733A1 (en) | 2014-01-09 |
CN103491975A (zh) | 2014-01-01 |
PE20140969A1 (es) | 2014-07-24 |
KR20140043709A (ko) | 2014-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY33872A (es) | Uso de análogos de glucagón acilados | |
BR112014015681A2 (pt) | análogos de glucagon | |
BR112015005783A8 (pt) | análogos de glucagon | |
BR112015001451A2 (pt) | análogos de glucagon | |
BR112013024076A2 (pt) | análogos de glucagon | |
UY34365A (es) | Compuestos heterociclicos | |
BR112016003454A2 (pt) | Uso de composto de metil bardoxolona | |
DK3410725T3 (da) | Referencebilledsignalering | |
BR112014008590A2 (pt) | métodos de uso de antagonistas de scd1 | |
BR112014023200A2 (pt) | uso de uma composição | |
UY34206A (es) | Anticuerpo monoclonal de interleucina-31 | |
UY34228A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9 | |
DK2693881T3 (da) | Substituerede n-phenylpyrimidin-2-amin-analoger som inhibitorer af axl-kinase | |
SMT201600410B (it) | Modulatori diidropirazolici di gpr40 | |
UY34074A (es) | Composición oftálmica de olopatadina altamente concentrada | |
UY33957A (es) | Moduladores de los receptores de hormonas nucleares | |
BR112014026926A2 (pt) | uso terapêutico de produtos de semente de chardonnay | |
UY33906A (es) | Composiciones herbicidas que comprenden topramezona | |
UY33909A (es) | Metodo para producir fibra de lignina | |
BR112013024784A2 (pt) | análogos de peptídeos de ação prolongada | |
BR112014003027A2 (pt) | formulação herbicida melhorada | |
BR112014013660A2 (pt) | uso de uma partícula | |
CO6801700A2 (es) | Uso demetilhidroxietilcvelulosacomo aditivo de cemento | |
EP2672926A4 (en) | RESTORATION OF ACCOMMODATION BY FILLING THE CRYSTALLINE | |
BR112013018812A2 (pt) | projetor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20200422 |